STOCK TITAN

PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PLUS THERAPEUTICS director Ronald Asbury Andrews exercised equity awards, acquiring additional common stock through RSU vesting. On July 1, 2026, 922 Restricted Stock Units converted into 922 shares of common stock at a stated price of $0.00 per share as part of his compensation. Following the transaction, he directly holds 922 shares of common stock and 2,764 Restricted Stock Units that represent rights to receive the same number of shares, vesting in four substantially equal quarterly installments beginning on July 1, 2026.

Positive

  • None.

Negative

  • None.
Insider ANDREWS RONALD ASBURY
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 922 $0.00 --
Exercise Common Stock 922 $0.00 --
Holdings After Transaction: Restricted Stock Units — 2,764 shares (Direct, null); Common Stock — 922 shares (Direct, null)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.
Common shares acquired 922 shares Converted from RSUs on July 1, 2026
Common shares held after 922 shares Direct ownership following the transaction
RSUs held after 2,764 units Restricted Stock Units outstanding after conversion
RSUs converted 922 units RSUs converted into common stock on July 1, 2026
Stated conversion price $0.00 per share Price per share for RSU conversion
Vesting structure Four quarterly installments Beginning on July 1, 2026 for the RSU grant
Restricted Stock Units financial
"Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSU financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise or conversion financial
"transaction_action": "derivative exercise/conversion""
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ANDREWS RONALD ASBURY

(Last)(First)(Middle)
6420 LEVIT GREEN BOULEVARD
SUITE 310

(Street)
HOUSTON TEXAS 77021

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026M922(2)A$0(1)922D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$007/01/2026M922 (2) (2)Common Stock922$02,764D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
2. Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.
Andrew Sims, as attorney-in-fact07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PLUS THERAPEUTICS (PSTV) report for Ronald Asbury Andrews?

PLUS THERAPEUTICS reported that director Ronald Asbury Andrews acquired 922 shares of common stock on July 1, 2026. The shares came from the vesting and conversion of 922 Restricted Stock Units, a routine equity compensation event rather than an open-market stock purchase or sale.

How many PLUS THERAPEUTICS (PSTV) shares did Ronald Asbury Andrews acquire in this Form 4 filing?

Ronald Asbury Andrews acquired 922 shares of PLUS THERAPEUTICS common stock. These shares resulted from the exercise and conversion of 922 Restricted Stock Units at a stated price of $0.00 per share, reflecting equity compensation rather than a cash purchase in the open market.

What are the remaining Restricted Stock Units reported for Ronald Asbury Andrews at PLUS THERAPEUTICS (PSTV)?

After the reported transaction, Ronald Asbury Andrews held 2,764 Restricted Stock Units. Each RSU represents a contingent right to receive one share of PLUS THERAPEUTICS common stock, providing additional potential future share ownership as these units continue to vest over time.

How do the PLUS THERAPEUTICS (PSTV) RSUs for Ronald Asbury Andrews vest over time?

Ronald Asbury Andrews’ Restricted Stock Units vest in four substantially equal quarterly installments beginning on July 1, 2026. This schedule spreads the equity compensation over one year, with each vesting date converting a portion of RSUs into common shares at the stated terms.

Was there any open-market buying or selling in the PLUS THERAPEUTICS (PSTV) Form 4 for Ronald Asbury Andrews?

The Form 4 for Ronald Asbury Andrews shows no open-market buying or selling activity. It reports an M-code transaction classified as an exercise or conversion of derivative securities, in which Restricted Stock Units converted into common stock as part of his equity compensation.

What does the M transaction code mean in the PLUS THERAPEUTICS (PSTV) Form 4 for Ronald Asbury Andrews?

The M transaction code in this Form 4 indicates an exercise or conversion of a derivative security. For Ronald Asbury Andrews, it reflects Restricted Stock Units converting into 922 shares of PLUS THERAPEUTICS common stock rather than a direct purchase or sale on the open market.